CGP of cfDNA from 7,707 unique men with advanced prostate cancer was available to assess the presence of mutations in BRCA1 and/or BRCA2. The median age for the total cohort was 72 years (interquartile range 65-78 years). This evidence concerns the gene BRCA1 and prostate cancer.